Time to capitalise on Hikma’s ongoing (share price) momentum
17/05/24 -"We have incorporated higher royalty payments in 2024 related to the sale of the generic version of sodium oxybate (medicine to treat symptoms of narcolepsy, i.e. sudden muscle weakness and excessive ..."
Pages
51
Language
English
Published on
17/05/24
You may also be interested by these reports :
11/03/26
BioNTech’s full-year results revealed sales surpassing expectations, although the operating loss was higher than anticipated. The 2026 sales guidance ...
11/03/26
While we acknowledge the upcoming HIV patent expiries (c.17% of sales) starting 2027-28, we remain encouraged by GSK’s execution ability as it ...
06/03/26
We have incorporated the 2025 reported figures and added a new forecast year (2028) to our model. Consequently, we have reduced the out-year sales ...
05/03/26
The Q4 results fell somewhat short of expectations, as Life Science and Healthcare witnessed decent growth, whereas the quarter was tough for ...